The development of a new antivascular drug to fight cancer in dogs has received backing from Eurostars, a European programme dedicated to supporting innovative research and development projects.

From left: Susan North (VRCC), Andrei Popov (Ecrins Therapeutics) and Barbara Kaser-Hotz (AOI) at the formal signing of the CADAC consortium agreement.

The transnational programme – which has a €1.4 billion (£989 million) budget to help research-performing small and medium sized enterprises develop innovative products, processes and services – is backing development of the drug to the tune of €1.6 million (£1.1 million).

The drug is being developed by French pharmaceutical company Ecrins Therapeutics, in conjunction with the Animal Oncology and Imaging (AOI) Center in Switzerland and VRCC, the UK’s leading private small animal cancer treatment centre.

Testing and development

Ecrins Therapeutics has already invested more than €2 million (£1.4 million) in developing the drug, and the Eurostars contribution will go towards further testing and development of this “new and exciting treatment option”, with the aim of bringing it to the market in a few years’ time.

Ecrins Therapeutics, the AOI Center and VRCC – the CADAC consortium – came 19th out of 323 in Eurostars’ eligible applications, and look forward to working together and playing an important contribution to the improvement of cancer treatment in dogs in the near future.
View your activity >

Leave a Reply

Be the First to Comment!

Notify of